Antibiotic dosing in obesity: The search for optimum dosing strategies

Clinical Obesity

Volumn 4, Issue 6, 2014, Pages 287-295

  Tucker, C E ^a   Lockwood, A M ^a   Nguyen, N H ^a  

^a St Vincent's Medical Center Jacksonville   (United States)

Author keywords

Antibiotics; Obesity; Pharmacokinetics

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFEPIME; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; NONHUMAN; OBESITY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; SURGICAL INFECTION; TREATMENT PLANNING;

EID: 84947864520     PISSN: 17588103     EISSN: 17588111     Source Type: Journal    
DOI: 10.1111/cob.12076     Document Type: Article

References (53)

1. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081-1091.
2. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17: e53-e62.
3. Brill M, Diepstraten J, Rongen A etal. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012; 51: 277-304.
4. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication 1998; 98-4083.
5. Bearden DT, Rodvold KA. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38: 415-426.
6. Pai MP, Paloucek FP. The origin of the 'ideal' body weight equations. Ann Pharmacother 2000; 34: 1066-1069.
7. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30: 18-32.
8. Hollenstein UM, Brunner M, Schmid R etal. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord 2001; 25: 354-358.
9. Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012; 32: 856-868.
10. Myers JW, Moorman JP, Salgado C, Gantz NM (eds). Gantz's Manual Of Clinical Problems In Infectious Disease. Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, 2013. Print.
11. Buehler KS, Yancey AM. Underdosing in obesity - an epidemic: focus on antibiotics. Formulary 2013. URL http://formularyjournal.modernmedicine.com.
12. De Baerdemaeker L, Mortier E, Struys M. Pharmacokinetics in obese patients. Br J Anaesth 2004; 4: 152-155.
13. Martin JH, Saleem M, Looke D. Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology. Br J Clin Pharmacol 2012; 73: 685-690.
14. Polotsky HN, Polotsky AJ. One size may not fit all: pondering antibiotic dosing in obesity. Maturitas 2010; 66: 381-382.
15. Bauer LA, Edwards WA, Dellinger EP etal. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24: 643-647.
16. Ho VP, Nicolau DP, Dakin GF etal. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt) 2012; 13: 33-37.
17. Rich BS, Keel R, Ho VP etal. Cefepime dosing in morbidly obese patient population. Obes Surg 2012; 22: 465-471.
18. Newman D, Scheetz MH, Adeyemi OA etal. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007; 1: 1734-1739.
19. Zakrison TL, Hillie DA, Namias N. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin/tazobactam. Surg Infect (Larchmt) 2012; 13: 38-42.
20. Chen M, Naffziger AN, Drusano GL etal. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal weight, obese and extremely obese adults. Antimicrob Agents Chemother 2006; 50: 1222-1227.
21. Pea F, Cojutti P, Sbrojavacca R etal. TD-guided therapy with daptomycin and meropenem in morbidly obese, critically ill patient. Ann Pharmacother 2011; 45: e37.
22. Taccone FS, Cotton F, Roisin S etal. Optimal meropenem concentrations to treat multidrug resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56: 2129-2131.
23. Betrosian AP, Frantzeskaki F, Xanthaki A etal. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56: 432-436.
24. Zobell JT, Waters CD, Young DC etal. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-122.
25. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375: 248-251.
26. Muzevich KM, Lee KB. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother 2013; 47: e25.
27. Pereira-Goncalves J, Paiva J. Dose modulation: a new concept of antibiotic therapy in the critically ill patient? J Crit Care 2013; 28: 341-346.
28. Blouin RA, Brouwer KL, Record KE etal. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-bypass surgery. Clin Pharm 1985; 4: 70-72.
29. Tsuji Y, Hiraki Y, Matsumoto K. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis 2012; 44: 626-629.
30. Tsuji BT, Brown T, Parasrampuria R etal. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of staphylococcus aureus. Antimicrob Agents Chemother 2012; 56: 3712-3719.
31. Tsuji BT, Bulitto JB, Brown T etal. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother 2012; 67: 2182-2190.
32. Bhalodi AA, Papasavas PK, Tishler DS etal. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 2013; 57: 1144-1149.
33. Allard S, Kinzig M, Boivin G etal. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993; 54: 368-373.
34. Allard S, Kinzig M, Boivin G, Sorgel F, LeBel M. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993; 54: 368-373.
35. Cook AM, Martin C, Adams VR etal. Pharmacokinetics of levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother 2001; 55: 3240-3243.
36. Itani KM, Jensen EH, Finn TS, Tomassini JE, Abramson MA. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt) 2008; 9: 131-137.
37. Caldwell JB, Nilsen AK. Intravenous ciprofloxacin dosing in a morbidly obese patient. Ann Pharmacother 1994; 28: 806.
38. Luque S, Grau S, Valle M etal. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. J Antimicrob Chemother 2011; 66: 1653-1654.
39. Kees MG, Weber S, Kees F, Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother 2011; 66: 2330-2335.
40. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-625.
41. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-580.
42. Lodise TP, Patel N, Lomaestro BM etal. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-514.
43. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-1336.
44. Reynolds DC, Waite LH, Alexander DP, Deryke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm 2012; 69: 944-950.
45. Stein GE, Schooley SL, Peloquin CA etal. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427-432.
46. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011; 55: 4006-4011.
47. Ortega A, Aldaz A, Giraldez J, Brugarolas A. Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours. Pharm World Sci 1999; 21: 227-232.
48. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650-655.
49. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-133.
50. Ulldemolins M, Roberts JA, Rello J etal. The effects of hypoalbuminaemia on optimizing antibacteria; dosing in critically ill patients. Clin Pharmacokinet 2011; 50: 99-110.
51. Medico CJ, Walsh P. Pharmacotherapy in the critically ill obese patient. Crit Care Clin 2010; 26: 679-688.
52. Udy AA, Varghese JM, Altukroni M etal. Sub-therapeutic initial beta-lactams concentrations in select critical ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-39.
53. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-351.